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ABSTRACT 
THE EFFECT OF 830NM LIGHT ON INFLAMMATION IN RETINITIS 
PIGMENTOSA 
by 
Krystal M. Bach 
The University of Wisconsin-Milwaukee, 2015 
Under the Supervision of Dr. Janis T. Eells 
 
Purpose:  Retinitis Pigmentosa (RP) is an inherited retinal degenerative disease 
and the most common cause of blindness in developed countries, affecting 
approximately 1 in 4,000 people. RP is characterized by photoreceptor cell death 
and recent studies suggest that chronic inflammation may play a key role in the 
pathogenesis of RP. Currently, there are no known treatments or preventive 
measures to delay or halt the loss of photoreceptor cells. Photobiomodulation 
(PBM) by light in the far-red or near-infrared (NIR) range of the light spectrum 
has been documented to help promote cell survival and reduce inflammation in 
several disease states. Recent studies in the P23H rat model of RP have shown 
that 830nm PBM attenuated photoreceptor cell loss and protected retinal 
function. The current studies test the hypothesis that 830nm PBM produces an 
anti-inflammatory environment in the retina to protect against photoreceptor cell 
loss. 
Methods:  Studies were conducted in compliance with the ARVO Statement for 
the Use of Animals in Ophthalmic and Visual Research. P23H rats were 
irradiated with 830nm light (180 s; 25 mW/cm2; 4.5 J/cm2) using a light-emitting 
diode array once per day from postnatal day (p)17 to 27. Sham treated controls 
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were restrained for 180 seconds, but not exposed to the 830nm light. Retinas 
were harvested at p30. Retinal concentrations of ten inflammatory mediators 
were determined using a multiplex bead-based immunosorbent assay. 
Results: Our findings indicate that retinal concentrations of four of the ten 
inflammatory mediators, CINC-3, IL-10, VEGF, and TIMP-1 differed between the 
dystrophic P23H rats and the non-dystrophic SD rats. Statistically significant 
differences were only observed in TIMP-1, with concentrations in the P23H 
retinas that were twice that measured in the SD retinas. 830nm PBM produced 
no changes in retinal concentrations of the 10 inflammatory mediators measured 
compared to the sham treatment.  
Conclusion:  Our data indicated that the inflammatory environment of the 
dystrophic P23H rat and the non-dystrophic SD rat differ. The data also shows 
that 830nm PBM had no measurable effect on these inflammatory mediators at 
p30. Further studies with greater numbers of animals are needed to investigate 
the time course of inflammation in this rodent model of RP and to define potential 
effects of PBM.   
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CHAPTER 1: INTRODUCTION 
 
I. Background 
 
Retinitis Pigmentosa 
 
Etiology 
 
Retinitis Pigmentosa (RP) is a group of inherited retinal degenerative 
diseases that cause the progressive loss of vision due to the death of 
photoreceptor cells. RP is the most common cause of blindness in developed 
countries and affects approximately 1 in 4,000 people, worldwide (1-5).  RP is an 
extremely heterogenic disease with multiple modes of inheritance. It is estimated 
that 30-40% of all RP cases are caused by autosomal dominant mutations, 50-
60% are caused by autosomal recessive mutations, 5-15% are X-linked, and a 
small portion exhibit complex polygenic inheritance and non-Mendelian 
inheritance (1, 5-7). In addition, RP has been associated with over 30 different 
syndromes. These syndromic conditions account for 20-30% of all RP cases (1, 
8, 9). The most common RP syndromes are Usher syndrome (10-20% of RP 
cases) and Bardet-Biedl syndrome (5-6% of RP cases) (1, 8, 10). 
Over 45 gene loci have been shown to be involved in RP, with genetic 
mutations affecting a wide variety of metabolic pathways. Mutations have been 
characterized in the phototransduction cascade, from protein trafficking to 
metabolic functions, and in cellular structures both inside and outside the ocular 
tissues (1, 8, 9). Although most mutations only account for a very small 
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percentage of RP cases, there are few exceptions. The most commonly affected 
genes are RPGR, USH2A, and RHO. Together, mutations in these three genes 
represent 30% of all RP cases (1, 9). Mutations in the RHO gene, which encodes 
for the G-protein coupled photon receptor rhodopsin, are the most common. 
These mutations are present in 25% of autosomal dominant cases of RP, and 8-
10% of all cases of RP (1, 11-14). 
RHO is a highly conserved 7,000 base pair gene among vertebrates (11, 
15). It codes for a 348 amino acid light sensitive protein, also known as an opsin. 
Opsin is a seven segment transmembrane protein located in the discs of the 
outer segments of photoreceptor cells. The seven transmembrane segments 
form a pocket with a lysine residue in the middle. This residue binds the 
chromophore 11-cis-retinal, which is derived from vitamin A (11). It is this 
chromophore and opsin together that form the visual pigment rhodopsin, which 
absorbs light in the eye initiating the visual cycle (15). Therefore, it is no surprise 
that defects in RHO have the potential to severely impair vision. Over 40 
mutations and deletions known to cause RP have been found in RHO (11, 16). 
These mutations impair normal protein folding and transportation, rhodopsin’s 
incorporation into the photoreceptor’s outer segments, the binding of 11-cis-
retinal, and the G-protein coupling and activation of rhodopsin (11, 15). 
Of the mutations affecting the rhodopsin molecule, the P23H mutation is 
the most commonly reported, causing 12% of all autosomal dominant RP cases 
(12, 17). The P23H mutation is caused by a single base-pair substitution, 
changing a cytosine to an adenine in the 23rd codon. Normally, this codon 
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produces the amino acid proline, but the mutation results in a histidine being 
placed at that location instead (17). The exact function of the proline at codon 23 
is unknown; however, this particular codon is very highly conserved, as it is 
present in the same location in other opsins and rhodopsin homologs of 
vertebrates and invertebrates alike (17). It has been demonstrated that the P23H 
mutant rhodopsin is misfolded due to the substitution. This misfolding results in 
the inability of the 11-cis-retinal chromophore to properly incorporate into the 
rhodopsin molecule. The mutant rhodopsin is also less photosensitive, and is 
rapidly degraded due to its instability in the cells (12). Approximately 10% of the 
mutant rhodopsin produced is successfully transported to the outer segments of 
the photoreceptors (18). This greatly impacts the rod photoreceptor cells’ ability 
to function, as 90% of all the proteins found in the outer segment are rhodopsin 
(15). The misfolded proteins that do successfully integrate into the outer segment 
membranes cause the photoreceptor cell to be structurally disorganized, and it 
has been proposed that this disorganization is a potential cause of the 
photoreceptor cell degeneration (18). In addition, the misfolded protein tends to 
aggregate in the endoplasmic reticulum (ER), where it is produced (12, 19, 20). 
The accumulation of misfolded proteins generates stress in the ER and activates 
the unfolded protein response (UPR). The UPR attempts to either repair or 
eliminate misfolded proteins by upregulating the production of the ER stress 
transducers inositol-requiring protein-1  (IRE-1), protein kinase RNA-like ER 
kinase (PERK), and activating transcription factor 6 (ATF6).  The molecular 
chaperone binding immunoglobulin protein (BiP), which is found in the lumen of 
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the ER, senses the misfolded rhodopsin proteins and activates the stress 
transducers. Once activated, IRE-1, PERK, and ATF6 promote the degradation 
of the misfolded proteins by either ER-associated protein degradation (ERAD) or 
autophagy (21). However, as the mutant proteins are constantly being 
reproduced, it is suggested that the UPR is overwhelmed as the cell cannot 
adapt to the constant stress or attenuate the UPR due to the excessive 
degradation occurring. This results in an increased production of reactive oxygen 
species (ROS), which triggers a cascade of pro-apoptotic signals, leading to the 
death of photoreceptor cells (19, 21, 22). 
 
Clinical Manifestations 
 
Although RP is actually an umbrella term for many similar yet 
heterogeneous retinopathies, RP is generally characterized by the degeneration 
rod photoreceptors followed by a secondary deterioration of the cone 
photoreceptors (1, 8). This step-wise degeneration of the photoreceptors makes 
the typical progression of the disease definable in three stages known as early, 
mid, and end stage RP (8).  
The early stage commonly occurs during the early or adolescent years (1, 
8). At this point, the rods are just beginning to degrade and the only symptom is a 
mild night blindness or difficulties adjusting to dark conditions. This is due to a 
ring scotoma, or blind spot, that begins to form in the mid-periphery of the visual 
field (1, 8, 11, 23). Symptoms at this stage can be easily missed as artificial 
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lighting may help conceal the defect, and the patient may not notice any 
difficulties during their day-to-day activities. Even if the patient is examined, tests 
are usually performed in light conditions that do not reflect the dark conditions 
needed to diagnose the loss of vision (1, 8). An examination of the retina is also 
of limited use at this stage, as the fundus has a relatively normal appearance 
with potentially only a slight attenuation of the retinal arterioles (8, 11, 23). 
During the mid-stage of the disease, the ring scotoma has progressed into 
the far-peripheral field of vision and is noticeable in day light conditions, as well 
as, at night (1, 17, 23, 24).  The night blindness is pronounced and affects routine 
activities (8). The patient may also begin to experience photophobia in diffuse 
light conditions (8). In addition, at this stage the cone photoreceptors are 
beginning to degenerate, and color vision may be affected. In particular, there is 
a decreased detection of pale colors such as blue and yellow (1, 8, 11). The 
retina begins to have an abnormal appearance. Bone-spicules, which are areas 
of exposed retinal epithelial (RPE) cells due to the death of the covering 
photoreceptor cells (25), are found in the periphery of the fundus. There is also 
an obvious narrowing of the retinal arterioles and a slight paling of the optic disc 
(8, 11, 23). At this stage of the disease, the development of cataracts is common, 
occurring in nearly 50% of RP patients (24, 26). With the constriction of the 
patient’s remaining vision into a central field, the development of a cataract can 
effectively blind the patient if not removed. Throughout the mid-stage the 
progression of the disease should be carefully monitored, as on average patients 
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lose 4.6% of their remaining vision per year (23). Once a patient’s visual field 
reaches 10 degrees or less, they are considered legally blind (24).   
The end stage occurs when the patient’s vision has decayed into a small 
central field known as tunnel vision (1, 8, 11, 23, 24). The restriction of the 
patient’s vision severely impairs their ability to function. Often, by the age of 40 
patients are legally blind, and can lose their remaining central vision by the age 
of 60 (1, 11). Although only photoreceptor cells degenerate during the early and 
mid-stages of RP, during the end stage, all retinal cells begin to degenerate (1), 
resulting in the atrophy of the retina. Furthermore, bone-spicules are found 
throughout both the macular and peripheral areas of the fundus, the optic disc 
has waxy appearance, and the retinal vessels are extremely attenuated (8, 11, 
17). 
RP can be clearly diagnosed and assessed during the latter half of the 
disease’s progression by examining the symptoms; however, attempting to 
assess RP during its early stages by identifying symptoms can be misleading. As 
mentioned before, patients often do not notice symptoms during the early stage 
and it is not until cone degeneration is already involved that patients may report 
symptoms. It has been observed that while 180 degrees is the normal field of 
vision, patients with only 130 degrees will not even notice the reduction in vision 
while performing daily tasks (27). A patient can lose up to 90% of their cones in 
the fovea before a reduction in vision is even perceived (28). Therefore, clinical 
assessments of RP need to measure the patient’s visual function directly to 
accurately diagnose early cases of RP.   
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Electroretinograms (ERGs) are one of the best methods for assessing the 
development of RP. This non-invasive procedure stimulates the photoreceptors 
with flashes of light. The electrical response is recorded using an electrode either 
placed on a contact lens or the eyelid. The response of the rod and cone 
photoreceptors can be measured together or separately depending on the stimuli 
used. A rod dominant response can be achieved by dark-adapting the patient’s 
eyes for 20 minutes, then exposing them to a single flash of dim blue light. A 
flickering 30Hz white light can be used in light-adapted condition to measure the 
response of only the cones, as stimulus greater than 20Hz are too fast for the 
rods to follow. To measure the overall response of both photoreceptors, a single 
bright white flash of light can be used. This produces an “a-wave,” which 
represents the initial hyperpolarization of the photoreceptors, and a “b-wave,” 
which is the subsequent depolarization of the bipolar cells. The amplitudes of 
each wave form and the time between peaks can be used to determine the 
functionality of the photoreceptor cells (29, 30). Patients with RP have decreased 
ERG a-wave and b-wave amplitudes and delayed response times, with the 
severity depending on the inheritance pattern of the disease and the stage of 
progression (29, 30).  ERGs can be used as effective tools to help diagnose RP, 
as abnormal responses can be detected years to decades before any symptoms 
even begin to develop (31). 
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Current Treatments 
 
 There is a large variability between patients with RP due to the genetic 
heterogeneity and individual environmental factors. This has made the 
development of effective treatments difficult.  Currently, the only treatable forms 
of RP are those caused by the three metabolic syndromic disorders (32).  
Bassen-Kornzweig disease, also known as abetalipoproteinemia, is an 
autosomal recessive disorder that results in the malabsorption of fats and the fat-
soluble vitamins A, D, E, and K. Among its other symptoms, the vitamin A 
deficiency causes retinal degeneration (33, 34). The loss of retinal function in 
these cases of RP can be reversed with high doses of vitamin A and E 
supplements if treated before permanent retinal damage occurs (33, 34). The 
second treatable syndromic RP condition is Refsum’s disease, also known as 
phytanic acid oxidase deficiency. Refsum’s disease is a lipid metabolism disorder 
resulting from a deficiency of phytanic acid hydroxylase. This deficiency causes 
an accumulation of the fatty acid phytanic acid in serum and tissues, including 
RPE cells, leading to their degeneration. By maintaining a low phytol and low 
phytanic acid diet, the development of RP can be avoided (35, 36). The last 
treatable syndromic RP condition is familial isolated vitamin E deficiency, or α-
tocopherol transport protein deficiency, which is caused by mutation in the α-
tocopherol transfer protein gene ttpA (37). This ttpA mutation prevents the proper 
absorption of vitamin E, resulting in neurodegeneration. High doses of vitamin E 
supplements are sufficient to counter the deficiency and prevent RP (37). 
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 With the exception of these three syndromic conditions, there has been 
limited success in developing effective therapies for RP. Gene therapies attempt 
to correct the defective biochemical pathways, but the method used depends on 
the specific mutation and inheritance type.  Autosomal Recessive mutations are 
often caused by a mutation which results in the loss of a function, and gene 
transfer therapies designed for these mutation aim to restore the wild type 
function. For example, RPE-/- dogs are a model of Leber congenital amaurosis 
(LCA), an inherited retinal degenerative disease similar to RP that occurs within 
the first few months or years of life. Animals affected with this disease lack an 
isomerase needed in the retinoid cycling process to change all-trans-retinal back 
into 11-cis-retinal. This deficiency results in the accumulation of all-trans-retinal 
and the degeneration of RPE and photoreceptor cells (38, 39). In a study 
performed by Acland et al., three four-month old RPE-/- dogs were injected in the 
subretinal space with a recombinant adeno-associated virus (rAAV) vector 
carrying the wild type RPE65. The results of ERGs, pupillary response times, and 
behavioral tests all showed significantly improved visual function 95 days after 
the injection (38).  The experiment was repeated with a larger sample size of 17 
dogs and demonstrated that the visual improvement was maintained for at least 
three years and retinal degeneration was reduced (39). These two studies were 
used as a proof of concept to initiate clinical trials of the gene therapy; however, 
when the patients who had received the rAAV-RPG65 therapy were examined, it 
was found that although visual function was improved for up to three years, the 
degeneration of photoreceptors was unabated (40). To further examine the 
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discrepancies between the canine models and clinical trials, Cideciyan et al. 
compared the natural progression of the disease in humans and various animal 
models. The RPE65-/- dogs had a slower rate of disease progression, with a 
dysfunctional only phase for 5-8 years before degeneration started, while 
humans did not have this period and dysfunction and degeneration happened 
simultaneously.  When the dogs were treated at an older age when the 
dysfunction and degeneration state matched the human disease state at the time 
of treatment, the gene therapy was unable to slow the rate of degeneration (40). 
 A different type of gene therapy is needed for cases of RP caused by 
autosomal dominant mutation, which normally results in the gain of an abnormal 
function or product. Gene silencing therapies attempt to inhibit or remove the 
abnormal gene product. RNA interference (RNAi) is one method currently being 
tested. A study performed by Li Jang et al. used a mouse model of autosomal 
dominate RP to study the long term effects of this technique. Subretinal injections 
of a rAAV vector carrying the RNAi cassette delayed the photoreceptor 
degeneration and increased visual function for up to 11 months in the mice (41). 
While these results are promising, clinical trials of RNAi gene silencing are still in 
progress and it is unknown if they will face the same problems as the gene 
transfer treatments. Even if the obstacles of treatment timing with gene therapy 
are overcome, a unique therapy is required for each mutation, and with only 60% 
of the causal mutations identified for RP (1), there is still a great deal of research 
to be done before gene therapy can be an effective treatment option for patients. 
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 Several dietary supplements are used as therapies to slow the rate of 
retinal degeneration, despite limited clinical evidence. A randomized clinical trial 
involving 61 RP patients with various inheritance patters demonstrated that 
15,000 IU/day of retinyl palmitate as a vitamin A supplement caused a modest, 
but significantly lower rate of decline in cone ERG amplitude over the course of 
four to six years. However, the rate of visual field and acuity loss did not differ 
from the controls (42). Because of this study, vitamin A supplements are 
recommended to patients with RP, even though the efficacy of the treatment is 
still questioned. In addition, there are potential negative side effects to the high 
doses of vitamin A that patients need to be aware of, such as liver toxicity, 
osteoporosis in postmenopausal women, and birth defects with pregnant women 
(43-45). Docosahexaenoic acid (DHA) is another dietary supplement has been 
used. DHA is an omega-3 fatty acid found in cell membranes, with particularly 
high concentrations in photoreceptor cells (46-48). Several studies have 
examined its effect on the visual function of RP patients, both alone and with 
other dietary supplements. The first study observed 44 males with X-linked RP 
who were given either 400mg of DHA per day or a placebo for four years. The 
patient’s ERGs, visual fields, acuity, dark adaptation, and fundus appearance 
was assessed annually along with the concentration of DHA found in the 
patient’s red blood cells (RBC). No significant differences were observed 
between the DHA group and the placebo despite significantly elevated levels of 
RBC DHA concentrations (46). A second study examining the effects of DHA 
increased the dose and combined it with vitamin A supplements in 208 patients 
12 
 
 
 
with various forms of RP. The patients were given either 1,200 mg of DHA with 
15,000 IU of retinyl palmitate per day, a control plus 15,000 IU/day of retinyl 
palmitate, or a control plus a placebo for four years. Again, no significant 
differences were observed in the annual ERGs or visual field and acuity of the 
patients (47). However, after further examination of the study’s subjects, it was 
noticed that the patients who were not taking any vitamin A supplements prior to 
the start of the study had slower rates of vision loss for the first two years when 
given DHA and retinyl palmitate. It was also noted that while the results were not 
significant, the patients who had the highest concentration of DHA in their RBCs, 
had the slowest rates of visual decline. Interestingly, in the control groups that 
were given only retinyl palmitate or a placebo, it was found that those who 
consumed 1.4mg/day or more of omega-3 fatty acids in their diet had 40-50% 
slower rates of visual field loss compared to those who did not (48). 
 Light protection is another approach to attenuate the rate of retinal 
degeneration. Animal models provide evidence that bright light exposure 
increases the degeneration rate of photoreceptors in RP (49), and that either light 
constraint or constant darkness can slow the rate of degeneration (50). However, 
case studies examining the effect of light constraint in human eyes has not 
shown any protective benefits. In two different case studies, a RP patient had 
one eye normally exposed to light and the other either experimentally covered for 
six hours a day or closed due to a childhood physical trauma (51, 52). In both 
cases, when the retinas of the exposed and protected eyes were compared, no 
differences were observed in the state of disease. However, these cases do not 
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take into account any potential systemic effects of the light exposure; therefore, 
more studies are needed to determine the full effect of light protection. Still, it is 
recommended to patients that they wear amber colored sunglasses with side 
protection to block ultraviolet and visible light up to 572nm to help reduce 
photophobia (8). 
 For the RP patients who have already lost their vision, there are few 
treatment options that attempt to restore the retinal tissue and visual function.  
Retinal transplants attempt to insert layers of various retinal and RPE cells into 
the subretinal space of a degenerated adult retina. However, while these 
transplanted donor cells seem to survive in the host, the new cells often do not 
function properly. The transplanted cells show no evidence of developing 
functional synaptic pathways with the host’s neurons, and the transplanted cells 
tend to form rosettes instead of organizing into the appropriate retinal layer. 
Similar difficulties have been observed with transplanted stem cells, as these 
cells do not seem to be able to integrate into the host’s retina and develop into 
photoreceptor cells (53).  Maclaren et al. proposed that these issues may be 
overcome if committed photoreceptor precursor cells were used instead of stem 
cells or developed cells. In 2006, Maclaren et al. demonstrated with a murine 
model that by harvesting the donor cells from a developing retina during the peak 
of rod photoreceptor genesis and injecting them into the subretinal space of an 
adult retina, the transplanted cells were able to integrate properly into the outer 
nuclear layer of the retina and develop into mature rod photoreceptors with the 
correct morphology. Furthermore, when transplanted in this manner into three 
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different murine models of inherited retinal degeneration, these cells were able to 
integrate into the degenerated retina, form functional synaptic connections, and 
improve visual function (53). Retinal prosthetics are another treatment that show 
promise for patients completely blinded by RP. Several studies testing 16-
electrode epiretinal implants in the eyes of patients blinded by RP have shown 
the device is able to allow the patient to sense light, directions of motion, and 
differentiate an object’s spatial orientation (54, 55). It is hoped that by increasing 
the electrode numbers and density in the implants, the patients will experience 
greater visual function with better resolution. 
 There is still much research to be done before a truly effective treatment 
option is available for patients with RP. Although much is known about the 
majority of the genetic mutations and the phenotypic manifestations, relatively 
little is known about the mechanisms of the disease. The heterogenetic nature of 
RP makes it unlikely that one treatment will be effective for all RP patients; 
increasing our understanding of the biochemical and cellular changes that drive 
the progression of RP is key to the development of any effective treatments.  
 
Ocular Immunity 
 
Immune Regulation 
 
 The eye is considered to be an immune privileged organ, meaning it has a 
unique tolerance to the presence of antigens, severely limiting any potential 
inflammatory response. The specialized cells found in the ocular tissue are highly 
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sensitive to damage, and like most neurons, are postmitotic and have limited 
regenerative capabilities (56). Therefore, the collateral damage caused by a 
robust inflammatory response may do more harm than good. The eye limits its 
immune reactivity using several different mechanisms. One mechanism it uses is 
known as anterior chamber associated immune deviation (ACAID). ACAID is a 
specialized method for developing systemic tolerance to retinal antigens. The 
local antigen presenting cells (APC) detect antigens found within the anterior 
chamber of the eye and carry them to the thymus and spleen to create a central 
tolerance to the retinal antigen. Antigen-specific regulatory T cells are also 
produced to impair reactive cell responses (57).  The blood retinal barrier (BRB) 
is another mechanism the eye uses to limit its immune reactivity. The endothelial 
cells of the retinal microvasculature are non-fenestrated and form tight junctions 
to prevent the passage of any large molecules or cells from the choroid to the 
retina. Likewise, the tight junctions between the RPE cells work as part of the 
BRB to maintain the homeostasis by controlling the transport of nutrients, waste, 
and ions between the photoreceptors and the choroid (58, 59).  The eye also 
lacks lymphatic drainage pathways to limit the movement of leukocytes and 
antigens (60). In addition to physically limiting the access of immune cells, many 
ocular cells have properties designed to suppress the immune response. For 
example, many ocular cells either lack or have a low expression of the major 
histocompatibility complex (MHC) class 1α protein to inhibit the activation of T 
cells. Many ocular cells also constitutively express the Fas ligand, which will 
trigger apoptosis in any lymphoid cells expressing the Fas receptor. Furthermore, 
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many immunomodulating proteins are expressed in the eye, such as 
complement-inhibiting proteins and anti-inflammatory cytokines like the 
membrane attack complex inhibitory protein (MAC-IP/CD59), and transforming 
growth factor β (TGF-β) (56, 60, 61). 
 Due to the immune separation of the eye from the rest of the body, the 
eye contains its own immunocompetent cells. The two predominant cells with 
critical immune functions are the retinal pigment epitheial (RPE) cells and 
microglial cells. The RPE is a single layer of cells between the photoreceptors 
and choroid, it performs many critical functions aside from being part of the BRB. 
The RPE acts as an attachment site, binding the rest of the retina to the choroid. 
It phagocytizes the shed discs from the photoreceptor cells, and it is involved in 
the retinoid cycling process needed to maintain visual function. Furthermore, the 
melanin pigment found within the RPE absorbs the excess scattered light in the 
eye to prevent damage to the retina (59). Moreover, the RPE plays a significant 
role in modulating both the innate and adaptive immune responses in the retina. 
RPE cells are capable of expressing both MHC class I and II proteins, allowing 
them to function as APCs in the retina. Additionally, they express a variety of 
factors including Fc-γ receptors, toll-like receptors (TLR), complement 
components, growth factors, and a variety of cytokines and chemokines (62-67). 
In particular, it has been demonstrated that RPE cell will express interleukin (IL)-
6, IL-8, and monocyte chemoattractant protein (MCP)-1 as pro-inflammatory 
cytokines, and interferon (IFN)-β, IL-11, and TGF-β as anti-inflammatory factors 
(66, 68). 
17 
 
 
 
 Microglial cells are the primary immunocompetent cell in the retina. They 
enter the retina early in embryonic development and work to maintain 
homeostasis as well as functioning at the resident macrophage in the eye (69). 
Microglia exist in two states, resting and activated. While the microglial cells are 
in the resting state they have a ramified morphology and are found primarily 
within the inner retina among the ganglion and bipolar cells (69-71). The 
microglia remain dormant in this state until they are activated by infectious 
agents, cellular debris, lipopolysaccharides, or reactive oxygen species (ROS) 
(69, 72, 73).  Once activated, the microglia enlarge to take on an amoeboid 
shape with enhanced abilities to proliferate, migrate, and phagocytize (69, 74).  
The microglia also release multiple cytokines and chemokines, which include 
MCP-1, IL-1β, IL-10, IFN-γ, macrophage inflammatory protein (MIP)-1α, and 
tumor necrosis factor (TNF)-α. The activated microglial cells will also produce 
neurotoxic factors including hydrogen peroxide and superoxide anion (75, 76). If 
the activating stimulus is readily removed, the microglia will return to their resting 
state; however, if the stimulus cannot be easily removed the microglia will adhere 
to the surface of the nearby neurons and begin to continuously produce the 
aforementioned factors, eventually causing the death of the neurons. The cellular 
debris created from the dying neurons along with this constant production of 
constituents activates and recruits additional microglia to the site causing 
neuroinflammation (69, 75). The excessive production of cytotoxins from the 
prolonged activation of microglial cells has been linked to neurodegeneration in 
many diseases including experimental herpes encephalitis, West Nile Virus 
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encephalitis, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral 
sclerosis (77-81). Moreover, in the retina, the activation and infiltration of 
microglial cells has been associated with the retinal degeneration observed in 
light induced retinal injury and multiple forms of inherited retinal degeneration, 
including RP (82-84).  
 
Inflammation 
 
 The term “Retinitis Pigmentosa” was first used by the Dutch 
ophthalmologist Dr. Franciscus Donders in 1857 to describe an ocular disorder 
that presented with night blindness and developed characteristic black pigment 
deposits on the retina. As the word retinitis is defined as “inflammation of the 
retina,” it was originally believed that inflammation was a key factor in the 
pathogenesis of the disease (85). For decades, studies have suggested that an 
immune response may be involved in RP. In 1962, serum samples from six of ten 
RP patients showed elevated levels of IgM antibodies in circulation (86). Again in 
1973, a similar study found significantly increased concentrations of IgM in 52 RP 
patients compared to 40 non-diseased patients (87). Moreover, a study 
performed in 1980 by Brinkman et al. demonstrated that patients with RP had an 
immunological response to retinal antigens while non-diseased patients did not. 
When Brinkman et al. exposed the RP patients’ blood samples to human retinal 
antigens or bovine rod outer segments, leukocytes migration, complement 
fixation, and lymphocyte activation was observed (88). Additionally, in 1988, 
macrophages, B cells, and various subsets of T cells were found in the vitreous 
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fluid of three biopsy samples and eight postmortem samples from RP patients. In 
each of the samples, two-thirds of the immune cells were found to be reactive, 
whereas the immune cells in the vitreous fluid from non-diseased eyes, which 
contained only a few macrophages, were mostly non-reactive (89). However, due 
to the heterogeneity of the disease, there were also reports that found no 
significant indication of inflammation. Because of these discrepancies, as the 
genetic mutations behind RP were discovered, it was generally accepted that the 
genetic defects were the primary cause of RP and the term “retinitis” was a 
misnomer (85).  
 Nevertheless, recent studies indicate that inflammation may play a key 
role in the pathogenesis of retinal degenerative diseases. Multiple studies 
performed in the 21st century have observed that the secretion of pro-
inflammatory cytokines and chemokines is integral in the pathogenesis of several 
retinopathies including macular edema, age-related macular degeneration 
(AMD), and diabetic retinopathy (90-93). Furthermore, during the examination of 
postmortem donor eyes from patients with AMD, late-onset retinal degeneration, 
and RP, large accumulations of activated microglia were detected within regions 
of the outer nuclear layer (ONL) where photoreceptor degeneration was 
occurring (83). These observations have prompted several researchers to once 
again investigate the relationship between inflammation and disease progression 
in RP. 
The rd mouse is a widely used animal model of RP. Using this model, 
Zeng et al. measured the production of mRNA and pro-inflammatory factors 
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throughout the course of photoreceptor degeneration. It was observed that just 
prior to the peak of cell death, there was a significant increase in the production 
of MCP-1, MCP-3, MIP-1, MIP-1β, regulated on activation normal T cell 
expressed and secreted (RANTES), and TNF-α. The chemokines caused the 
activation and migration of microglial cells that released the TNF-α in the ONL 
(94). Likewise, a study using porcine retinal explants treated with the 
phosphodiesterase 6 (PDE6) inhibitor Zaprinast as a new model of RP, noticed 
that an increased production of IL-6 and TNF-α was associated with the 
photoreceptor cell death (61). In a study using S334ter-4 rats, which have a 
mutation resulting in a truncated form of rhodopsin, a low dose of the synthetic 
corticosteroid fluocinolone acetonide (FA) was shown to mitigate the 
photoreceptor degeneration and preserve visual function. Intravitreous 
administration of 0.2μg/day of FA, attenuated the ERG amplitude loss by 85%. 
ONL thickness was preserved by 25.8% compared to the controls (six to eight 
cell rows versus three to four rows at 12 weeks), and there was a seven to eight 
times reduction in the presence of activated microglial cells in the photoreceptor 
cell layer (70).  Similar results were observed in CCL3-/-MERTK-/- mice. MERTK-/- 
mice are a murine model of RP, and the CCL3-/-MERTK-/- mice are unable to 
produce CCL3, also known as MIP-1α, which is necessary for the recruitment 
and activation of polymorphonuclear leukocytes. The lack of CCL3 preserved the 
ONL thickness, decreased the number of microglial and macrophage infiltrates, 
and increased the BRB integrity by 50% compared to the dystrophic MERTK-/- 
mice (71).   
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In further support of inflammation playing a pivotal role in the 
pathogenesis of RP, a set of studies performed by Yoshida et al. examined the 
characteristics of the inflammatory response in both humans with RP and a 
murine model (95, 96). In the clinical study, 371 RP patients and 165 control 
patients were examined. A slit-lamp biomicroscope analysis was used to count 
the number of cellular infiltrates present in the anterior vitreous cavity and 
compare it to a retrospective analysis of the patient’s visual function. It was found 
that while only two of the controls (1.21%) had five-to-nine cells per field in their 
eyes, 37.3% of the RP patients had five-to-thirty cells per field, with the younger 
patients commonly having the higher numbers. The RP patients with five or more 
cells per field had significantly lower visual function scores compared to both the 
control patients and RP patients with less or no cells in their anterior vitreous 
cavity. Biopsies were also taken from the aqueous and vitreous humors of all 
patients. It was observed that all RP patients had significantly elevated levels of 
IL-8, MCP-1, and thymus and activation-regulated chemokine (TARC). In 
addition, IL-6 was detected in 14 out of 16 RP samples while none was detected 
in any control samples. In the vitreous humor, IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, 
IL-10, IFN-γ, growth regulated oncogene-α, I-309, IFN-γ inducible protein (IP)-10, 
MCP-1, MCP-2, and TARC were all significantly elevated in the RP patients 
compared to the control patients (95). Taken together, these results suggest 
chronic inflammation occurs in RP and is related to its pathogenesis.  
To further investigate the role of inflammation, Yoshida et al. followed this 
clinical study up with a laboratory study using the rd10 mouse model of RP (96). 
22 
 
 
 
It was observed from real time polymerase chain reaction (PCR) of the RNA in 
the total retinal tissue that MCP-1, IL-1β, RANTES, and TNF-α were significantly 
upregulated by postnatal day (p)14, which is prior to the start of photoreceptor 
cell loss, and maintained throughout the disease course. Immunohistochemistry 
revealed that increased accumulations of Iba1+ activated microglial cells were 
found in the subretinal space, ONL, and outer plexiform layer of rd10 retinas at 
p14 and p21, while the retinas of wild type mice displayed none (96). Collectively, 
the results of these studies demonstrate that the inflammatory response has an 
integral role in the degeneration of photoreceptors in RP.  Therefore, it can be 
hypothesized that a treatment which is able to ameliorate the inflammation would 
be beneficial to patients with RP.  
  
Photobiomodulation 
 
The use of specific wavelengths of light to induce biological changes in 
cells is known as photobiomodulation (PBM) (97). It has been hypothesized that 
far-red to near infrared (NIR) light (630-900nm) interacts with cytochromes in the 
mitochondrial electron transport chain, triggering a cascade of intracellular events 
culminating in improved cell survival. Cytochrome c oxidase (CcO) is the most 
likely candidate to be this photoacceptor molecule, as the action spectrum for the 
cellular effects of PBM corresponds to the absorption spectrum of CcO (98-101). 
Nitric oxide (NO) competitively binds to CcO in mitochondria, replacing the 
oxygen normally bound, and thereby inhibits mitochondrial respiration (98, 99, 
102). When the NIR light reacts with CcO, it induces a conformational change 
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which causes the NO to disassociate from the CcO resulting in an increased 
production of adenosine triphosphate (ATP). The released NO has been 
postulated to trigger the activation of gene transcription factors that regulate the 
transcription of genes involved in many cellular functions, including apoptosis 
and inflammation (98-103).   
PBM has been shown to help promote healing, induce cell growth and 
survival, and reduce inflammation for a variety of conditions. For example, a 
study done by Muili et al. in 2012 treated C57BL/6 mice with experimental 
autoimmune encephalomyelitis (EAE), a murine model of multiple sclerosis, with 
670nm light and found that the disease was ameliorated. Evidence from 
quantitative real-time PCR suggested that the 670nm light modulated the disease 
by up-regulating the anti-inflammatory cytokines IL-10 and IL-4, while down-
regulating the pro-inflammatory cytokines IFN-γ and TNF-α (104).  Similarly, in a 
study performed by Assis et al., low-level laser therapy was used to treat muscle 
cryolesions, and it was observed to both significantly reduce oxidative stress and 
inflammation by modulating the gene expression of NF-κB and COX-2 (105). 
Another example is a study that used 810nm light to treat rheumatoid arthritis. 
The treatment not only showed an improvement in the arthritis, but a decrease in 
the intracellular levels of TNF-α, IL-1β, and IL-8 (106). These studies are just a 
few examples of different conditions in which PBM has been demonstrated to 
ameliorate disease manifestations. It is likely that PBM may be successfully used 
to ameliorate RP as well. 
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Supporting this theory, several studies using PBM on retinopathies have 
been performed with promising results. For instance, 670nm light has been used 
to treat methanol-induced retinal toxicity in male Long-Evans rats. The methanol 
intoxication results in retinal dysfunction and morphological changes in the 
photoreceptors. Treatment with 670nm light (4.5 J/cm2) for 144 seconds at five, 
24, and 50 hours after intoxication prevented the loss of retinal function and 
histopathological changes associated with methanol intoxication (98).  The 
treatment of light-induced photoreceptor degeneration with 670nm light under 
several different conditions (3 min/day at 5 J/cm2 for 2, 5, 7, or 10 days prior to 
light-injury, or 3 min/day at 9 J/cm2 for 5 days either prior, during, or after light-
injury) has been shown to be neuroprotective. The treatments attenuated the 
histological changes associated with the light damage, increased photoreceptor 
cell survival and function, reduced the production of the stress-related molecule 
glial fibrillary acidic protein (GFAP), modulated the production of neuroprotective 
proteins, and decreased the inflammatory response (97, 107). In a study of 
Retinopathy of Prematurity, which causes retina degeneration due to abnormal 
vascular development in premature babies, 670nm light (3min/day, 9 J/cm2) 
during hyperoxic exposure normalized retinal vascular development and 
significantly prevented photoreceptor cell death in oxygen-induced retinopathy 
mouse and rat models (108). In another PBM study performed by Kokkinopoulos 
et al., 670nm light set at 40 mW/cm2 was used to treat age-related retinal 
inflammation, and it was observed to significantly reduce inflammation, the 
production of TNF-α, and the inflammatory markers complement component 3d 
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and calcitonin (109). Similar results were observed by Begum et al. when using 
670nm to treat a complement factor H knockout murine model of AMD. In this 
study, 670nm light (6mins twice a day for 14 days, at 20 mW/cm2), used as part 
of the environmental lighting produced a significant reduction in the expression of 
complement component C3, the stress markers GFAP and vimentin, and 
increased the expression of CcO (101).  Moreover, when 830nm light 
(3mins/day, 25 mW/cm2, 4.5J/cm2) was used to treat the P23H rat model of RP 
during the peak time of photoreceptor loss, it was shown to attenuate the severity 
of the disease. The animals treated with the 830nm light had 50% greater ERG 
amplitudes for both rod and cone response, representing a significant 
preservation of retinal function. In addition, histological assessments 
demonstrated that the 830nm light protected against the loss of photoreceptor 
cells in the retina (110).  Collectively, these studies provide considerable 
evidence to support the application of NIR PBM as a viable treatment option for 
RP.  PBM could be used to delay or prevent the loss photoreceptor cells by 
modulating the inflammation response, reducing cell stress, and upregulating 
neuroprotective factors. PBM may offer a non-invasive treatment option for 
patients that is independent of inheritance pattern and can be effectively initiated 
after the disease is diagnosed and photoreceptor degeneration has already 
begun. 
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II. Hypothesis and Specific Aims 
 
RP is the most common cause of blindness in developed countries, 
affecting approximately 1 in 4,000 people worldwide (1-5). Evidence suggests 
chronic inflammation in the retina is a key factor in the pathogenesis of RP, 
resulting in the degeneration of the photoreceptor cells (86-96). Currently, there 
is no known treatment or preventive measure to halt the loss of photoreceptor 
cells in RP. PBM offers a possible method to treat RP as it has been shown to 
alleviate inflammation and preserve photoreceptor cell morphology and function 
in other retinopathies (97, 98, 101, 107-109). Recent studies in the P23H rat 
model of RP have shown that treatment with 830nm light significantly attenuated 
photoreceptor degeneration and protected against the loss of visual function 
(110). Considerable evidence supports the modulation of cytokine and 
chemokine expression as a primary mechanism by which PBM mitigates 
inflammation (104-106); thus it is likely that NIR light treatment attenuates 
photoreceptor degeneration by up-regulating anti-inflammatory mediators and 
down-regulating pro-inflammatory mediators. The overall goal of this study is to 
determine the anti-inflammatory actions of 830nm light in the P23H rat model of 
RP. 
 
 The hypothesis of this study is that treatment with 830nm light promotes 
an anti-inflammatory environment in the retina. The specific aims listed below 
were designed to test this hypothesis. 
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1. Compare the concentrations of pro-inflammatory mediators in the 
retinas of non-dystrophic SD rats with P23H rats and determine 
the effect of 830nm light on pro-inflammatory mediators in the 
retina of SD and P23H rats. The working hypothesis for this specific 
aim is that there are differences in the pro-inflammatory mediators in 
the retinas of P23H and SD rats and that treatment with the 830nm 
light will reduce the retinal concentrations of pro-inflammatory 
mediators. 
2. Compare the concentrations of anti-inflammatory mediators in the 
retinas of non-dystrophic SD rats with P23H rats and determine 
the effect of 830nm light on anti-inflammatory mediators in the 
retina of SD and P23H rats.  The working hypothesis for this specific 
aim is that there are differences in the anti-inflammatory mediators in 
the retinas of P23H and SD rats and that treatment with the 830nm 
light will increase the retinal concentrations of anti-inflammatory 
mediators.  
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CHAPTER 2: MATERIALS AND METHODS 
 
I. Animal Model 
 Male and female Sprague-Dawley (SD) rats were obtained from Harlan 
Sprague Dawley Inc. (Madison, WI). The albino SD rats were used as non-
dystrophic controls for retinal degeneration. Male and female homozygous P23H 
transgenic rats were provided by the Retinal Degeneration Rat Model Resource 
at the University of California, San Francisco. The homozygous P23H transgenic 
rats were crossbred with the SD rats to produce heterozygous P23H transgenic 
rats. The P23H transgenic rat is a widely accepted model RP as it bears a single 
amino acid substitution at codon 23, which results in photoreceptor degeneration 
similar to humans with RP caused by the autosomal dominant P23H mutation 
(111). Heterozygous P23H rats are used instead of homozygous P23H rats 
because they more accurately reflect the human genetic condition and disease 
development, and the rate of retinal degeneration has been well defined for 
heterozygous P23H rats (112). 
All animals were bred and housed in the American Association for 
Accreditation of Laboratory Animal Care approved facility in Lapham Hall at the 
University of Wisconsin-Milwaukee. The animals were housed in an environment 
which is humidity controlled and maintained at 21°C.  The animals were provided 
with food and water ad libitum and kept in a dim 12 hour light-and-dark cycle, 
with an average of illuminance of 5-10 lux.  All procedures were approved by the 
Institutional Animal Care and Use Committee of the University of Wisconsin-
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Milwaukee and were conducted in compliance with the Association for Research 
in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic 
and Visual Research. 
 
II. Near Infrared Light Treatment 
Previous studies have demonstrated that using the wavelength of 830nm 
was effective at attenuating the degeneration of photoreceptor cells (110). For 
this reason, a wavelength of 830±10nm from a Gallium/Aluminum/Arsenide 
(GaAIA) light-emitting diode (LED) array (QDI, Barneveld WI) was used for 
treatment. The treatment was initiated on postnatal day (p) 17, and continued 
daily until p27.  Once per day, rats were placed in a clear polypropylene box with 
the LED array placed on top. Each treatment consisted of 830±10nm irradiation 
for 180 seconds at a light intensity of 25mW/cm2 resulting in a dose, or fluence, 
of 4.5J/cm2. This dose of fluence of light has been documented to attenuate the 
production of inflammatory cytokines in other disease models (98, 104).  
Treatment controls were sham-treated by being restrained for 180 seconds in the 
box with the array placed on top, but not exposed to the 830nm light. 
 
III. Tissue Collection 
 The rats were euthanized at p30 by CO2 inhalation. Whole eyes and 
retinas were collected from the rats immediately after euthanasia. Enucleated 
eyes were punctured with a pointed scalpel at the corneal limbus and 
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immediately immersed in 4% paraformaldehyde in 0.1 M phosphate-buffered 
saline (PBS). The eyes were stored in the 4% paraformaldehyde overnight, then 
transferred to a 4% sucrose solution in 0.1 M PBS and stored at 4°C. From the 
non-enucleated eye, retinas were harvested. Eyes were held with a forceps at 
the optic nerve while a 3-5mm incision was made in the corneal limbus. By 
pulling the forceps from the optic nerve to the cornea, the retina was extracted 
from the eye and immediately flash frozen in liquid nitrogen. The retinas were 
stored at -80°C prior to analysis. 
 
IV. Evaluation of Protein Concentration 
 Three or four retinas were pooled per sample. Each sample was 
suspended in lysis buffer (10% protein inhibitor cocktail in PBS). The volume of 
lysis buffer used was determined by multiplying the total retinal weight by 10 and 
dividing by the number of retinas pooled. The tissue was then homogenized by 
sonication. The samples were kept on ice during homogenization and sonicated 
using a set of two 15 second pulses with a five second rest at 50% amplitude. 
The samples were checked for uniform homogenization, then centrifuged at 
13,000xg for five minutes at 4°C. The supernatant was collected and the pellet 
discarded. The total protein concentration in each sample was then determined 
using a Pierce™ Bicinchoninic Acid (BCA) Assay Kit from Thermo Scientific 
according to the manufacturer’s instructions. Each sample was analyzed in a 
1:10 and 1:100 dilution with PBS and compared to a standard curve ranging from 
0 mg/mL to 2 mg/ml. The absorbance was measured for 570nm.   
31 
 
 
 
 
V. Assessment of Cytokine and Chemokine Concentrations 
 Retinal samples were collected and homogenized by sonication.  Samples 
were stored at -80°C until the analysis was performed. The concentrations of 
cytokine-induced neutrophil chemoattractant-3 (CINC-3), IL-1α, IL-6, IL-13, TNF-
α, IFN-γ, IL-4, vascular endothelial growth factor (VEGF), IL-10 and tissue 
inhibitor of metalloproteinase-1 (TIMP-1) were analyzed using R&D Systems’ 
Magnetic Luminex Screening Assay kit. This assay is a multiplex bead based 
sandwich enzyme-linked immunosorbent assay (ELISA) designed to quantitate 
multiple cytokines and chemokines in serum, plasma, and tissue culture 
supernatants. All procedures were performed according to the manufacturer’s 
instructions.  A Bio-Rad Bio-Plex analyzer (Dr. Coburn’s Lab, Medical College of 
Wisconsin) was used to measure the concentration of each cytokine and 
chemokine in pg/ml. Each sample was replicated, and analyzed compared to a 
standard curve. The standard curve was constructed using a 3-fold dilution 
series, with seven standards ranging from a 1:3 dilution to a 1:2,187 dilution. 
Results were normalized to the total amount of protein in each sample.  
 
VI. Statistics 
 The data was analyzed using a one-way analysis of variance (ANOVA) 
followed by the Bonferroni post-hoc test. Alpha was set at 0.05 for all P-value 
calculations to determine statistically significant differences between groups. 
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CHAPTER 3: RESULTS 
 
I. Rationale 
 
 Much is known about the phenotypic presentations of RP and the genetic 
mutations that cause it. However, very little is known about the mechanisms 
responsible for the pathology of RP. Although some investigators consider the 
term “retinitis pigmentosa” to be a misnomer with respect to inflammation being 
involved in pathogenesis, recent studies have provided evidence that chronic 
inflammation in the retina is a key factor in initiating and propagating the 
degeneration of photoreceptor cells in RP (86-96). NIR light has been 
demonstrated to reduce inflammation and improve visual function and 
photoreceptor cell survival in several other retinopathies (97, 98, 101, 107-109). 
Moreover, previous experiments using the P23H rat model of RP have 
demonstrated that treatment with 830nm light significantly attenuated the loss of 
visual function and photoreceptor cell degeneration (110). Since PBM has been 
shown to reduce inflammation by upregulating anti-inflammatory mediators and 
downregulating pro-inflammatory mediators in various conditions (104-106), it is 
suspected that the modulation of cytokines and chemokines produced in the 
retina is a primary mechanism by which the 830nm light reduced the severity of 
disease in the P23H rat. The purpose of this experiment was to assess the effect 
of the 830nm light on the concentration of inflammatory mediators found in the 
P23H rat retina. However, since inflammation in this model of RP has not been 
previously characterized, any differences in the retinal concentrations of the 
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inflammatory mediators in the P23H rat compared to the non-dystrophic 
Sprague-Dawley rat were assessed first. Characterization of the inflammatory 
cytokines and chemokines associated with disease in this model may lead to 
possible potential therapeutic strategies for the treatment of RP.   
The retinal concentrations of the following pro-inflammatory and anti-
inflammatory mediators were determined in this study because they have been 
either implicated as major immune regulators in the rat eye or shown to be 
significantly elevated in other models of RP: 
1) Cytokine-Induced Neutrophil Chemoattractant (CINC)-3: Also 
known as MIP-2, CINC-3 is a pro-inflammatory chemokine of the CXC 
subfamily. Its human analog is known as growth regulated oncogene 
(GRO) of the IL-8 family. As its name suggests, CINC-3 is the primary 
neutrophil chemotactic factor found in rats, resulting in the infiltration of 
neutrophils at sites of inflammation. It is primarily produced by monocytes 
and macrophages, but has also been shown to be produced by epithelial 
cells (113, 114). Moreover, the acute intraocular inflammation caused by 
endotoxin induced uveitis in Lewis rats has been associated with 
increased concentrations of CINC in the serum and aqueous humor (142). 
2) Interleukin (IL)-1α: IL-1α is a pro-inflammatory cytokine produced by 
macrophages and epithelial cells. It is known to cause T cell and 
macrophage activation and has been shown to stimulate the production of 
other pro-inflammatory factors, such as IL-1β and granulocyte-
macrophage colony stimulating factor in RPE cells (115, 116). 
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 3) IL-6: IL-6 is a pro-inflammatory cytokine produced by T cells, 
macrophages, endothelial cells, and in the retina, Müller glial cells, and 
RPE cells. It is known to have a wide range of effects on the inflammatory 
response. In particular, it stimulates the proliferation and differentiation of 
B and T cells, and triggers the production of acute phase reactants. The 
production of IL-6 has been associated with the pathogenesis caused by 
chronic inflammation in a variety of diseases, including RP (61, 95, 115, 
117). 
4) Tumor Necrosis Factor (TNF)-α: TNF-α is a pro-inflammatory cytokine 
produced by macrophages, natural killer (NK) cells, and T cells. TNF-α 
has multiple functions in the immune response, including stimulating the 
proliferation, differentiation, and survival of immune cells, mediating 
cytotoxic effects, and increasing vasodilation and vasopermeability. In the 
retina, it has been shown to be produced primarily by glial cells and has 
been associated with retinal degeneration in multiple retinopathies, such 
as glaucoma, AMD, RP, and ischemic retinopathy (61, 91, 92, 94, 96, 118, 
119). 
5) Interferon (IFN)-γ: IFN-γ is a pro-inflammatory cytokine that is 
produced by CD4+ TH1 cells, CD8+ T cells, and NK cells. The primary role 
of IFN-γ is to activate macrophages, but it also increases MHC 
expression, antigen processing, and Ig class switching, and suppresses 
TH2 cells. IFN-γ is generally not present in the ocular tissues of healthy 
eyes, and its presence has been associated with many ocular diseases. It 
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has been observed to cause intraocular cellular infiltration, microglia cell 
proliferation, and photoreceptor cell death (115, 120). 
6) Vascular Endothelial Growth Factor (VEGF): VEGF is a protein 
produced by a variety of cells that stimulates vaculogenesis and 
angiogenesis. In the retina, VEGF is primarily produced by RPE cells. The 
production of VEGF is often induced by hypoxic conditions in order to 
restore adequate oxygen supply to the cells. However, the overexpression 
of VEGF has been shown to cause vascular leakage and neural retina 
degeneration, implicating it in retinal diseases like AMD, diabetic 
retinopathy, and RP (121, 122). 
7) IL-4: IL-4 is an anti-inflammatory cytokine produced by CD4+ TH2 cells, 
mast cells, and basophils. It is involved in regulating the TH2 immune 
response by promoting the differentiation of TH2 cells instead of TH1 cells 
from naïve T cells. IL-4 also drives the antibody response by helping to 
initiate the proliferation and clonal expansion of B cells. A recent study 
using murine models has demonstrated that IL-4 is primarily expressed in 
the eye by RPE, choroid, and scleral cells. It was also shown that IL-4 had 
the ability to suppress the proliferation of retinal progenitor cells and 
promote their differentiation into rod photoreceptor cells in neonatal mice 
(115, 123). 
8) IL-13: IL-13 is an anti-inflammatory cytokine produced by TH2 cells. 
Like IL-4, IL-13 promotes the growth and differentiation of B cells and 
inhibits the differentiation of TH1 cells. Moreover, it also inhibits the 
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production of pro-inflammatory mediators such as IL-1, IL-6, TNF-α, IL-8, 
and MIP-1α from macrophages and monocytes. In addition, treatments 
with IL-13 have been shown to reduce inflammatory in rat models of acute 
ocular inflammation (115, 124). 
9) IL-10: IL-10 is an anti-inflammatory cytokine produced by monocytes, 
macrophages, and T cells. Together with IL-4, IL-10 promotes the TH2 cell 
response instead of the TH1 cell response. In addition, IL-10 can inhibit the 
expression of pro-inflammatory mediators from other cells. Studies have 
shown that in the retina, photoreceptor cells are capable of producing IL-
10 in response to IL-27 produced by microglia cells. Furthermore, 
endogenous and exogenous IL-10 has been observed to reduce 
inflammation in uveitis (125, 126).  
10) Tissue Inhibitor of Metalloproteinase (TIMP)-1: TIMP-1 is a 
glycoprotein which inhibits the matrix metalloproteinase (MMP)-9. MMPs 
are endopeptidases capable of degrading extracellular matrices. In the 
retina, TIMP-1 is found in the interphotoreceptor matrix, which is between 
the photoreceptors and RPE, and it is suggested that RPE cells may be 
responsible for the secretion of TIMP-1. In multiple retinal degenerative 
diseases, TIMP-1 has been observed to be significantly increased. 
Furthermore, intravitreal injections of TIMP-1 in a S334-ter-line-3 rat 
model of RP demonstrated that TIMP-1 is capable of helping to restore the 
homogeneity of photoreceptors in the retina by preventing the formation of 
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photoreceptor rings around areas of cell death and causing the remaining 
photoreceptors to be evenly spaced throughout the retina. (127, 128).  
 
II. Compare the concentrations of pro-inflammatory mediators in 
the retinas of non-dystrophic SD rats with P23H rats and 
determine the effect of 830nm light on pro-inflammatory 
mediators in the retina of SD and P23H rats. 
 
Concentrations of Pro-Inflammatory Mediators in the P23H Rat Retina 
The retinal concentrations of six pro-inflammatory mediators were 
measured: CINC-3, IL-1α, IL-6, TNF-α, IFN-γ, and VEGF.  No statistically 
significant differences were observed between the P23H retina and the SD 
retina. However, we saw trends that were opposite of what we anticipated. 
Retinal concentrations of five of the six pro-inflammatory mediators were lower in 
the P23H rat than the SD rat. The average IL-6 retinal concentration was 813 
pg/mL/mg retinal protein in the SD rat, while it was 683 pg/mL/mg retinal proteins 
in the P23H rat (16% less) (Figure 1). Likewise, TNF-α was found at an average 
concentration of 96 pg/mL/mg retinal protein in the SD rat and 79 pg/mL/mg 
retinal protein in the P23H rat (18% less) (Figure 2). Somewhat greater 
differences were observed in the mean retinal concentrations of IFN-γ, VEGF, 
and CINC-3. Retinal concentrations of IFN-γ and VEGF were 29% and 36% 
lower, respectively, in the P23H retina compared to the SD retina (268 pg/mL/mg 
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retinal protein vs. 192 pg/mL/mg and 90 pg/mL/mg vs 137 pg/mL/mg) (Figures 3 
and 4). Of all the pro-inflammatory mediators, CINC-3 showed the greatest 
difference. The mean concentration of CINC-3 in the P23H retinas was 52% 
lower than that measured in the SD retina (26 pg/mL/mg retinal protein vs. 54 
pg/mL/mg) (Figure 5).  IL-1α was the only cytokine of the six pro-inflammatory 
mediators measured to have a higher mean retinal concentration in the P23H 
rats. However, the average IL-1α concentration was still nearly identical in the 
retinas of the two animals, as the P23H rat had only a 5% increase compared to 
the SD retinal concentration (120 vs. 115 pg/mL/mg retinal protein) (Figure 6).  
 
 
Figure 1. Concentration of IL-6 found in retinal samples of sham treated 
Sprague-Dawley rats (n=4), 830m light treated Sprague-Dawley rats (n=5), 
sham treated P23H rats (n=5), and 830nm P23H rats (n=6). Retinal samples 
were obtained at p30. Error bars indicate SEM. No statistically significant 
differences (P<0.05). 
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Effects of 830nm Light on Retinal Concentrations of Pro-Inflammatory Mediators 
 No significant differences were observed in the retinal concentrations of 
the pro-inflammatory mediators between the sham treated and 830nm light 
treated rats. The standard error of the mean was large for each mediator 
measured, due to the small sample sizes used. The changes observed due to 
the 830nm light treatment were very minor, as the greatest reduction was only 
13% with TNF-α (Figure 2). IL-6 was reduced by 11%, and VEGF was 4% less in 
the light treated P23H rats compared to the sham treated (Figures 1 and 4). IL-1α 
displayed no differences with the light treatment, as the average retinal 
concentration remained at 121 pg/mL/mg retinal protein (Figure 6). Similarly, the 
Figure 2. Concentration of TNF-α found in retinal samples of sham treated 
Sprague-Dawley rats (n=4), 830m light treated Sprague-Dawley rats (n=5), 
sham treated P23H rats (n=5), and 830nm P23H rats (n=6). Retinal samples 
were obtained at p30. Error bars indicate SEM.  No statistically significant 
differences (P<0.05). 
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average retinal concentration of IFN-γ after the 830nm light treatment was only 
2% greater than the sham treated P23H rats (Figure 3). CINC-3 was the only 
pro-inflammatory mediator to be increased by more than a marginal amount with 
the 830nm light. Its average retinal concentration was 19% greater in the light 
treated P23H rats compared to the sham treated P23H rats (Figure 5).  
 In contrast to the P23H rats, the retinal concentrations of all six pro-
inflammatory mediators were increased in the SD rats treated with the 830nm 
light compared to the sham treated SD rats. Still, none of these differences were 
statistically significant. However, while most of the changes observed between 
the P23H rats were marginal, the differences between the light treated SD rats 
Figure 3.  Concentration of IFN-γ found in retinal samples of sham treated 
Sprague-Dawley rats (n=4), 830m light treated Sprague-Dawley rats (n=5), 
sham treated P23H rats (n=5), and 830nm P23H rats (n=6). Retinal samples 
were obtained at p30. Error bars indicate SEM.  No statistically significant 
differences (P<0.05). 
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and sham treated rats were generally larger. The increases ranged between 11% 
and 42% for IFN-γ and TNF-α, respectively (Figures 3 and 2).  
 
Figure 4. Concentration of VEGF found in retinal samples of sham treated 
Sprague-Dawley rats (n=4), 830m light treated Sprague-Dawley rats (n=5), 
sham treated P23H rats (n=5), and 830nm P23H rats (n=6). Retinal samples 
were obtained at p30. Error bars indicate SEM. No statistically significant 
differences (P<0.05). 
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Figure 6. Concentration of IL-1α found in retinal samples of sham treated 
Sprague-Dawley rats (n=4), 830m light treated Sprague-Dawley rats (n=5), 
sham treated P23H rats (n=5), and 830nm P23H rats (n=6). Retinal samples 
were obtained at p30. Error bars indicate SEM.  No statistically significant 
differences (P<0.05). 
Figure 5. Concentration of CINC-3 found in retinal samples of sham treated 
Sprague-Dawley rats (n=4), 830m light treated Sprague-Dawley rats (n=5), 
sham treated P23H rats (n=5), and 830nm P23H rats (n=6). Retinal samples 
were obtained at p30. Error bars indicate SEM.  No statistically significant 
differences (P<0.05). 
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III. Compare the concentrations of anti-inflammatory mediators 
in the retinas of non-dystrophic SD rats with P23H rats and 
determine the effect of 830nm light on anti-inflammatory 
mediators in the retina of SD and P23H rats. 
  
Concentrations of Anti-Inflammatory Mediators in the P23H Rat Retina 
 Four anti-inflammatory mediators were measured with the Magnetic 
Luminex Screening assay: IL-13, IL-4, IL-10 and TIMP-1. There was no 
difference between the average P23H and SD retinal concentrations of IL-13, as 
both contained approximately 39 pg/mL/mg retinal protein (Figure 7). There was 
20% more IL-4 present in the P23H retina than the SD retina (26 pg/mL/mg vs. 
21 pg/mL/mg) respectively, yet this was not statistically significant (Figure 8). 
Figure 7. Concentration of IL-13 found in retinal samples of sham treated 
Sprague-Dawley rats (n=4), 830m light treated Sprague-Dawley rats (n=5), 
sham treated P23H rats (n=5), and 830nm P23H rats (n=6). Retinal samples 
were obtained at p30. Error bars indicate SEM.  No statistically significant 
differences (P<0.05). 
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Likewise, there was no statistically significant difference between the P23H and 
SD retinal concentrations of IL-10. However, the average P23H retinal 
concentration of 21.44 pg/mL/mg retinal protein was 33% less than the average 
retinal concentration of 32 pg/mL/mg retinal protein observed in the SD retina 
(Figure 9). Conversely, the retinal concentrations of TIMP-1 was significantly 
greater in the P23H rat compared to the SD rat (P=0.008). The average level of 
TIMP-1 observed in the P23H retina was 96% greater than what was observed in 
the SD retina, at 24,357 pg/mL/mg retinal protein compared to 9,234 pg/mL/mg 
retinal protein (Figure 10). 
 
Figure 8. Concentration of IL-4 found in retinal samples of sham treated 
Sprague-Dawley rats (n=4), 830m light treated Sprague-Dawley rats (n=5), 
sham treated P23H rats (n=5), and 830nm P23H rats (n=6). Retinal samples 
were obtained at p30. Error bars indicate SEM.  No statistically significant 
differences (P<0.05). 
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Effects of 830nm Light on Retinal Concentrations of Anti-Inflammatory Mediators 
 No significant differences were observed in the retinal concentrations of 
the anti-inflammatory mediators between the sham treated and 830nm light 
treated rats. The trends that we observed in the P23H rats indicated that the 
830nm light treatment decreased the retinal concentration of all four of the anti-
inflammatory mediators. IL-4 displayed the greatest change, with a 24% 
reduction in the light treated rats compared to the sham treated rats (Figure 8). 
IL-13 was observed to have a 19% reduction, and IL-10 was reduced by 12% 
(Figures 7 and 9). TIMP-1 had the least alteration of its retinal concentration 
Figure 9. Concentration of IL-10 found in retinal samples of sham treated 
Sprague-Dawley rats (n=4), 830m light treated Sprague-Dawley rats (n=5), 
sham treated P23H rats (n=5), and 830nm P23H rats (n=6). Retinal samples 
were obtained at p30. * denotes a statistically significant difference 
(P<0.05). Error bars indicate SEM.   
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caused by the 830nm light treatment, being reduced by only 4% compared to the 
sham treated P23H rats (Figure 10).  
 The opposite trends were observed in the SD rats. All of the anti-
inflammatory mediators were found to be elevated in the light treated SD rats 
when compared to the sham treated SD rats. The most notable difference of this 
group was in the average retinal concentration of TIMP-1, which was observed to 
be 9,234 pg/mL/mg retinal proteins in the sham treated SD rats and 16,561 
pg/mL/mg retinal protein in the light treated SD rats, a 45% increase (Figure 10). 
Figure 10. Concentration of TIMP-1 found in retinal samples of sham treated 
Sprague-Dawley rats (n=4), 830m light treated Sprague-Dawley rats (n=5), 
sham treated P23H rats (n=5), and 830nm P23H rats (n=6). Retinal samples 
were obtained at p30. * denotes a statistically significant difference (P<0.05). 
Error bars indicate SEM. 
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 Furthermore, the retinal concentration of IL-10 was found to be 
significantly greater in the SD light treated rats compared to the P23H light 
treated rats (P=0.00028) (Figure 9). 
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CHAPTER 4: DISCUSSION 
 
The secretion of inflammatory cytokines and chemokines has been 
associated with the pathogenesis of multiple retinopathies, including AMD, 
diabetic retinopathy, and late-onset retinal degeneration (83, 90-93). Following 
these observations, the concept that inflammation was involved in RP was 
renewed. PBM, which is the use of light to induce a biological change in cells, 
has been demonstrated to reduce inflammation for a variety of conditions (98-
109). Recent experiments have shown that 830nm PBM is capable of 
significantly alleviating RP in the P23H transgenic rat model. The 830nm PBM 
preserved rod and cone ERG responses and prevented the loss of photoreceptor 
cells (110). However, the mechanism by which the 830nm light attenuated 
disease is unknown. Since the reduction of inflammation by up-regulating anti-
inflammatory mediators and down-regulating pro-inflammatory mediators has 
been reported in a variety disease states following PBM (104-106), we 
hypothesized that the modulation of cytokines and chemokines may be a primary 
mechanism by which the 830nm PBM ameliorated the degeneration of the 
photoreceptor cells in the P23H rat. However, the inflammatory profile of the 
retina of the P23H rat has never been characterized. For this reason, the 
following specific aims were designed to assess the association of cytokines and 
chemokines with retinal degeneration in the P23H rat, and determine the effect of 
830nm light on the inflammatory mediators in the retina of the P23H rat. 
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1. Compare the concentrations of pro-inflammatory mediators in the 
retinas of non-dystrophic SD rats with P23H rats and determine the 
effect of 830nm light on pro-inflammatory mediators in the retina of 
SD and P23H rats. The working hypothesis for this specific aim is that 
there are differences in the pro-inflammatory mediators in the retinas of 
P23H and SD rats and that treatment with the 830nm light will reduce the 
retinal concentrations of pro-inflammatory mediators. 
 
2. Compare the concentrations of anti-inflammatory mediators in the 
retinas of non-dystrophic SD rats with P23H rats and determine the 
effect of 830nm light on anti-inflammatory mediators in the retina of 
SD and P23H rats.  The working hypothesis for this specific aim is that 
there are differences in the anti-inflammatory mediators in the retinas of 
P23H and SD rats and that treatment with the 830nm light will increase 
the retinal concentrations of anti-inflammatory mediators. 
 
I. Compare the concentrations of pro-inflammatory mediators in 
the retinas of non-dystrophic SD rats with P23H rats and 
determine the effect of 830nm light on pro-inflammatory 
mediators in the retina of SD and P23H rats. 
 
Retinas were harvested from the dystrophic P23H rats and the non-
dystrophic SD rats at postnatal day (p)30 to compare the retinal concentrations of 
the selected inflammatory mediators. Interestingly, pro-inflammatory cytokine and 
chemokine concentrations did not differ between P23H and SD retinas. 
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Unexpectedly, the concentrations of most of the pro-inflammatory mediators 
appeared to be slightly lower in the retinas of P23H rats than those of the SD 
rats. Due to the large variability in individual values and the small sample size, 
statistical significance was not obtained. The concentrations of two pro-
inflammatory mediators, CINC-3 and VEGF, appeared to be substantially lower 
in the retinal tissue from P23H rats compared to SD rats. The retinal 
concentration of CINC-3 in the P23H retina was approximately half of that 
measured in the SD retina. As cellular infiltration of the retina has been one of 
the most constant observations of previous clinical and laboratory studies of 
inflammation in RP (70, 71, 83, 95, 96), it was surprising to find that the primary 
neutrophil chemotactic factor of rats was not elevated. However, while IL-8 and 
GRO, which are in the same family as CINC-3, have been shown to be 
significantly elevated in the aqueous and vitreous humors of human patients with 
RP (95), neither CINC-3 nor MIP-2 have been observed in rat or murine models 
of RP. Therefore, it is possible that CINC-3 is not involved in the recruitment of 
microglia or other immune cells infiltrating the retina in this model of RP. Similarly 
to CINC-3, the concentrations of VEGF in the P23H retinas were one-third less 
than that measured in the SD retinas. This was also contrary to what we 
anticipated, as elevated levels of VEGF have been implicated in the 
pathogenesis of retinal diseases, including AMD, diabetic retinopathy, and RP. 
For example, the overexpression of VEGF has been demonstrated to cause 
vascular leakage and retinal degeneration in Royal College of Surgeon (RCS) 
rats (122). Also, the intravitreal injection of bevacizumab, which is an anti-
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angiogenesis drug that suppresses VEGF, into RP patients has been shown to 
preserve the central macular thickness (121). These results suggest that 
increased concentrations of VEGF may be associated with retinal degeneration; 
however, one of the clinical manifestations of RP is the attenuation of retinal 
arterioles, which becomes progressively more severe as the disease develops 
(8, 11).  Since the primary function of VEGF is angiogenesis (121, 122), the 
continued attenuation of the retinal arterioles may suggest that while VEGF 
expression may be involved in the initiation of disease, its expression decreases 
as the disease progresses. In this experiment, retinal tissues were harvested at 
p30, after the disease has significantly developed (135). For this reason, the 
expression of VEGF may have decreased in the dystrophic P23H rats compared 
to the non-dystrophic SD rats.  
In order to assess the effect of the 830nm light on the pro-inflammatory 
mediators, dystrophic P23H rats and non-dystrophic SD rats were either treated 
with 830nm light or sham treated for 10 days, starting at p17. Retinal tissue was 
harvested from the light treated and sham treated rats at p30, and cytokine and 
chemokine concentrations were measured and compared. No significant 
differences in the retinal concentrations were detected between sham treated 
and 830nm light treated rats. Yet, there was a slight reduction in the average 
retinal concentration of three of the six pro-inflammatory mediators measured. 
While these differences were minor, because of the small sample size and the 
timing of the retinal harvest these lowered concentrations may suggest an anti-
inflammatory influence of the 830nm light. 
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II. Compare the concentrations of anti-inflammatory mediators in 
the retinas of non-dystrophic SD rats with P23H rats and 
determine the effect of 830nm light on anti-inflammatory 
mediators in the retina of SD and P23H rats. 
 
 The only anti-inflammatory mediator that was observed to be 
significantly different between the P23H rat and the SD rat was TIMP-1. The 
retinal concentration of TIMP-1 in the P23H retina was nearly double that 
measured in the SD retina. This finding partially supports our hypothesis, in that 
the imbalance of TIMPs and the MMPs they inhibit have been implicated in the 
pathogenesis of central nervous system inflammatory diseases and retinal 
degeneration (127, 128, 129). TIMP-1 has additional roles in beyond inhibiting 
MMPs, such as activating growth factors, inhibiting angiogenesis, promoting cell 
proliferation, and upregulating anti-apoptotic processes (130).  Furthermore, the 
secretion of MMPs and TIMPs by astrocytes and microglial cells has been shown 
to be induced by IL-1β, TNF-α, and lipopolysaccharides during states of 
inflammation (131). MMPs are often disproportionately elevated compared to the 
TIMPs, overwhelming the inhibition; however, the elevated expression of TIMP-1 
has been suggested as a biomarker for the severity of diseases associated with 
chronic inflammation. For example, in studies of inflammatory bowel disease and 
liver fibrosis from chronic hepatitis B, serum levels of TIMP-1 have been 
demonstrated to be significantly correlated with the degree of inflammation 
observed in patients (136, 137).  Additionally, a study examining the expression 
of MMPs and TIMPs in experimental autoimmune encephalomyelitis (EAE) found 
that the expression of TIMP-1 was restricted to activated astrocytes surrounding 
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inflammatory lesions (129).  Therefore, the significant elevation of TIMP-1 in the 
retinas of the P23H rats may suggest an inflammatory retinal environment.  
No differences in concentrations of the anti-inflammatory cytokines IL-4 
and IL-13 were observed between the dystrophic P23H retinas and the non-
dystrophic SD retinas. The retinal concentration of IL-10 in the P23H rat was 
one-third less than what was measured in the retina of the SD rat. This difference 
was not statistically significant; however, due to the small sample sizes and large 
variability, it may still indicate a potential difference between the P23H and SD 
retinas. IL-10 is a potent anti-inflammatory cytokine capable of suppressing the 
expression of multiple pro-inflammatory mediators for macrophages and TH1 
cells, such as IL-1β, IL-6, IL-8, TNF-α, and IFN-γ (115, 126, 138). Consequently, 
IL-10 deficiency has been linked to intensified and prolonged inflammation 
responses in multiple disease states (125, 139, 140, 141). Thus, if the lower 
retinal concentrations of IL-10 observed in the P23H retinas compared to the SD 
retinas can be confirmed in future studies with larger sample it sizes, it would 
support our hypothesis by suggesting pro-inflammatory environment in retina of 
the P23H rat. 
It was expected that the 830nm light treatment would increase the retinal 
concentrations of the anti-inflammatory mediators, but in this experiment it was 
observed that the concentrations of all four anti-inflammatory mediators were 
decreased. However, these reductions were not statistically significant. 
Additionally, the standard error of the mean was extremely large for each 
mediator measured. Taken together, these results indicate that the 830nm PBM 
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had no effect on the retinal concentrations of the anti-inflammatory mediators. 
Interestingly, a significant difference was observed between the light treated 
P23H rats and light treated SD rats in the retinal concentration of IL-10. This 
significant difference may support the potential difference between the untreated 
P23H and SD rats’ IL-10 retinal concentrations discussed above. The light 
treated sample sizes contained one more rat than the untreated sample sizes, 
this slight increase may have allowed the significant difference to be detected.   
 
III. Discussion 
  
 Studies have shown that the peak photoreceptor degeneration in the 
P23H rat occurs at approximately postnatal day 20 (112, 135). Moreover, the 
inflammatory response has been shown to precede photoreceptor cell loss (94, 
96). Thus, it is possible that we were unable to detect differences in the retinal 
concentrations of the pro-inflammatory and anti-inflammatory mediators between 
the P23H rats and the SD rats in our study because we harvested retinal tissue 
after the peak of inflammation in this model. In the heterozygous P23H rat, the 
majority of photoreceptors are lost by p60, with the peak of photoreceptor 
degeneration occurring at approximately p20. At p30 the photoreceptors are still 
degenerating, but at a significantly slower rate than at the p20 peak (112, 135). If 
inflammation is a factor in driving the degeneration of photoreceptors in the P23H 
transgenic rat model of RP, then the production of inflammatory mediators is 
likely to be predominately occurring prior to, or during, the peak of photoreceptor 
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cell death. By p30, the immune system may have adapted the chronic 
inflammation and returned the majority of cytokine and chemokine production to 
homeostasis in the retina.  
This reasoning that the timing of our retinal harvest was too late to 
observe elevated concentrations of our chosen inflammatory mediators is 
supported by the evidence provided in the studies performed by Zeng et al. and 
Yoshida et al., which observed the production of pro-inflammatory factors during 
the disease course of murine models of RP.  Zeng et al. measured the apoptosis 
of photoreceptor cells in the rd mouse at p8, 10, 12, 14, 16, and 18 and found 
that the photoreceptor cell death began at p10 and peaked at p16. Additionally, 
Zeng et al. demonstrated that the production of MCP-1, MCP-3, MIP-1, MIP-1β, 
RANTES, and TNF-α was significantly increased by p8 and peaked at p12. This 
corresponded with the activation of microglial cells, which started at p10 and 
peaked by p14 (94). Likewise, using the rd10 mouse model of RP, Yoshida et al. 
demonstrated that the retina expression of MCP-1, IL-1β, RANTES, and TNF-α 
was significantly upregulated by p14 prior to the start of photoreceptor cell loss. 
This upregulated expression was maintained throughout the course of the 
disease; however, the expression of MCP-1 and TNF-α was halved by p17 and 
continued to decrease through p21 and p28. Similarly, the IL-1β expression was 
nearly 10 times less by p17. The retinal expression of RANTES was the only 
factor measured to increase over time from p17 to p28 (96).  Since Zeng et al. 
and Yoshida et al. show that the pro-inflammatory mediators were produced 
mainly before photoreceptor cell death, these results suggest that a better 
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strategy to assess the role of inflammation in the retinal degeneration of the 
P23H rat would involve a time course. Additional studies should be performed to 
establish the time course of cytokine and chemokine expression during the onset 
and development of disease in the P23H rat. Since the photoreceptor cell loss 
peaks at p20 in this model of RP, it is suggested the expression should be 
measured beginning at p5 and again at p10, p15, p20, p25, and p30.  
Achieving measurable concentrations of each inflammatory mediator was 
another difficulty with this experiment that may have masked the effects of the 
830nm light. Due to the small size of the rat eye, retinas needed to be pooled in 
groups of three or four to obtain sufficient concentrations for the screening assay 
used. This greatly limited the sample size of each group, and may have limited 
the assay’s ability to detect statistically significant differences. In future 
experiments, quantitative real-time PCR may be used to determine the level of 
mRNA for each inflammatory mediator. This technique has been used to 
measure the expression of cytokines and chemokines in the retinas of murine 
models of RP (94, 96), and may be a more accurate method when dealing with 
small tissue samples. Also, it is possible that the cytokines and chemokines 
primarily associated with the retinal inflammation in the P23H rat were not among 
the 10 factors tested in this experiment. The pro-inflammatory factors MCP-1, IL-
1β, MIP-1, and RANTES are additional potential targets to investigate, as these 
factors have been shown to be significantly elevated in several murine models of 
RP as well as patients with RP (71, 94-96). 
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 The finding that the light treatment had no significant effects on the retinal 
concentrations of the cytokines and chemokines measured is unsurprising due to 
the minimal signs of inflammation observed at the time examined. If inflammation 
is not a significant factor in the pathogenesis of the disease, then there is no 
response for the NIR light treatment to down-regulate. Furthermore, the timing of 
the retinal harvest may have been inadequate to accurately measure the effect of 
the 830nm light treatment. As discussed earlier, the majority of the production of 
pro-inflammatory factors is likely occurring prior to or during the peak of 
photoreceptor cell loss (94-96).  In addition, as demonstrated by Yoshida et al. in 
the rd10 mouse, the expression of inflammatory factors can change rapidly. In 
the three day period between the initial and next sequential measurement, the 
retinal expression of MCP-1, TNF-α, and IL-1β was reduced by half or more (96). 
Therefore, any significant modulation of the inflammatory response due to the 
830nm light treatment is likely occurring in the first half of the 10 day treatment, 
when the rate of photoreceptor degeneration is highest (112). In order to verify 
the effect of 830nm PBM, a time course study examining the retinal 
concentrations prior, during, and immediately after the light treatment is 
suggested. 
There is also the possibility that the 830nm light treatment had no effect 
on the inflammatory response of the P23H rat. In this experiment, the 830nm 
light was used in order to replicate the methods used in the previous study using 
the P23H rat model of RP. However, this wavelength may not be the most 
effective treatment.  While the NIR wavelengths between 630-900nm have been 
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shown to be reactive with cytochrome c oxidase (CcO) and able to modify 
cellular functions in order to promote cell growth and survival, the efficacy of 
each wavelength is different. During the comparison of the absorption spectrum 
of CcO and its activity after exposure to various far-read and NIR wavelengths, it 
was demonstrated that wavelengths of 670nm and 830nm both corresponded 
with the peaks of absorbance and activation (132). For this reason, these two 
wavelengths have commonly been used for the treatment of various conditions. 
However, the most effective wavelength and treatment parameters are 
dependent on the condition, the affected tissue type, and location being treated 
(102, 133, 134).  
 A study performed by Giacci et al. examined the efficacy of 670nm and 
830nm light treatments in four different rat models of central nervous system 
injury, which included a light-induced retinal degeneration model. It was found 
that the efficacy of each wavelength varied by the injury type. In the case of the 
light induced retinal degeneration, it was demonstrated that a five day pre-
treatment with 670nm light (3mins/day at 3.4J/cm2) was able to significantly 
reduce the amount photoreceptor cell death after injury, but a five day pre-
treatment with 830nm light (3min/day at 2.7J/cm2) was not (134). Additionally, 
when a reduction of inflammation was observed in other studies using NIR light 
to treat retinal degeneration, 670nm light was used instead 830nm light (97, 101, 
107, 109). Taken together, this suggests that using 670nm light with the P23H rat 
model of RP may provide a greater effect on the retina’s inflammation response 
than the 830nm light.  
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In summary, the working hypothesis of aim 1 was that there are 
differences in the pro-inflammatory mediators in the retinas of P23H and SD rats 
and that treatment with the 830nm light will reduce the retinal concentrations of 
pro-inflammatory mediators. The data provided by this experiment did not 
support this hypothesis, as no significant differences in retinal concentrations of 
the pro-inflammatory mediators were observed between P23H and SD rats; nor 
were significant differences observed between the 830nm light treated rats and 
sham treated rats. The working hypothesis of aim 2 was that there are 
differences in the anti-inflammatory mediators in the retinas of P23H and SD rats 
and that treatment with the 830nm light will increase the retinal concentrations of 
anti-inflammatory mediators. The data provided by this experiment partially 
support this hypothesis, as a significant difference between the P23H rat and SD 
rat in the retinal concentrations of TIMP-1 was observed, which may suggest an 
inflammatory environment in the retina of the P23H rat. In addition, the retinal 
concentration of IL-10 was lower in the P23H retinas than the SD retinas, 
signifying a potential inability to regulate an exacerbated or prolonged 
inflammatory response occurring in the retina. While this difference was not 
statistically significant between the untreated P23H and SD rats, it was 
significantly different between the light treated P23H and SD rats. We suspect 
that if the sample size was increased, a significant difference would be observed. 
However, no significant differences were observed in the anti-inflammatory 
mediators between the 830nm light treated rats and the sham treated rats. 
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After comparing the experimental design of this study with the design of 
previous studies examining the production of inflammatory mediators in animal 
models of RP, we conclude that the timing of the retinal harvest may have been 
too late to evaluate the expression of inflammatory cytokines and chemokines in 
the retina of the P23H rat and to observe the effects of the light treatment. 
Additional experiments will be needed to establish a time course for the 
expression of cytokines and chemokines through the disease course of the P23H 
rat, beginning prior to the start of photoreceptor cell death. Once a time course is 
established, further experiments with the 830nm light are needed to measure the 
retinal concentrations of the inflammatory mediators prior to treatment, during 
treatment, and immediately after treatment in order to verify the effect of 830nm 
light on the production of inflammatory mediators in the retina of the P23H rat. 
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CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS 
 
 RP is the most common cause of blindness in developed countries, 
affecting 1 in 4,000 people (1-5). RP was first described in 1857 (85). Since then, 
the clinical manifestations of the disease have been well characterized and over 
half the genetic mutations responsible for RP have been identified (1). Despite 
this, little is known about the mechanisms of the disease. Despite considerable 
efforts, there are currently no effective treatment or preventative measures for 
RP. Photobiomodulation using light in the far-red to NIR range of the spectrum 
has been shown to attenuate inflammation, improve retinal function, and prevent 
photoreceptor cell death in several other retinopathies (97, 98, 101, 107-109). 
Recent investigations using the P23H rat model of RP provide evidence that both 
670nm and 830nm PBM protect against photoreceptor cell death (110). Taken 
together, these studies provide considerable evidence to support the application 
of NIR light as a potential treatment for RP. However, PBM must achieve FDA 
approval before it will be used to treat patients. In order to gain this approval, the 
mechanism by which the NIR light functions to ameliorate disease it must be 
identified. The objective of this thesis to contribute to this knowledge by 
characterizing the role of retinal inflammation in the pathogenesis of RP and 
determining if reducing inflammation is a mechanism by which PBM attenuates 
retinal degeneration.  
 These experiments tested the hypothesis that 830nm light promotes an 
anti-inflammatory environment in the retina. Overall, the hypothesis of this study 
was only partially supported, as no effects of the 830nm PBM were observed, but 
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differences seen in the cytokine and chemokine retinal concentrations suggested 
inflammation is occurring in the P23H rat retina. These results are novel as this is 
the first study to investigate inflammation in the P23H rat, which is a widely used 
model of RP. Moreover, the results of this study aid in characterizing the role of 
inflammation in RP, as not many studies have examined the role of inflammation 
in the pathogenesis of RP despite its implication in initiation and propagation of 
other retinal degenerative diseases (90-93). Establishing a role of inflammation in 
RP allows for the development of potential treatment options for patients by 
identifying a mechanism that can be manipulated to delay or halt the 
degeneration of photoreceptor cells. Supporting this idea of targeting 
inflammation for the treatment of RP, intravitreal injections of fluocinolone 
acetonide (FA) in several other rat models of retinal degeneration have been able 
to reduce microglia cell activation and migration, as well as preserve visual 
function and prevent photoreceptor cell death (70).  Therefore, additional 
experiments comparing the effects of intravitreal FA injections and NIR light 
treatments in the P23H rat should be performed. In addition to providing 
evidence that could demonstrate a causal role for inflammation in the 
pathogenesis of RP, by comparing the results of the NIR light treatment and the 
FA treatments, the modulation of inflammation may be verified as a mechanism 
by which NIR light attenuates photoreceptor degeneration in the P23H rat.  
In order to fully characterize the inflammatory response in the retina of the 
P23H rat model of RP and elucidate the protective mechanisms of PBM, future 
experiments should be designed to evaluate the complete inflammatory pathway.  
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For example, the presence of cellular infiltrates and the migration of microglia 
cells from the inner nuclear layer to the outer nuclear layer has been associated 
with the photoreceptor degeneration observed in both humans and animals with 
RP (70, 71, 83, 89, 94-96). Therefore, a histological analysis of the activation and 
infiltration of immune cells in the retina of the P23H rat would not only assess the 
presence of an inflammatory response, but provide information about the type of 
immune cells involved. Identifying the primary immune cells infiltrating the ocular 
tissues of the P23H rat could help determine which cytokines and chemokines 
are likely being expressed. This information could then be used to optimize the 
measurement of inflammatory changes caused by PBM. Alternatively, measuring 
the gene expression of NF-κB or other inflammatory transcription factors may be 
used to assess the regulation of inflammation in the retina (115), as NIR light 
treatments have been demonstrated to modulate the expression of NF-κB in 
other conditions (105). 
 Understanding the mechanisms of PBM is essential for achieving FDA 
approval, allowing it to be used for the treatment of RP patients. PBM may offer a 
non-invasive, easy to use treatment option with minimal side effects. Unlike gene 
therapy and steroid treatments, PBM does not use injections, eliminating the risk 
of infections or injury. The devices used to administer NIR light treatments can be 
small and preset, making them usable by patients at home. PBM also has the 
potential to be effective for a wide range of RP patients, as it is not targeted to 
specific mutations. Furthermore, an obstacle of other treatment methods has 
been the inability to halt photoreceptor cell death after degeneration has begun 
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(40). PBM has been shown to be able to preserve photoreceptor cells when 
treatment was initiated at the peak of photoreceptor cell death. This makes PBM 
an ideal treatment option since patients may have significant photoreceptor cell 
loss before RP is diagnosed (1, 8, 27, 28).  The insights obtained from this 
research advance our knowledge about the mechanisms behind RP and PBM, 
bringing an effective treatment one step closer to development for RP patients.  
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